Skip to main content

Table 4 Analysis of cost-effectiveness of each screening strategy

From: Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis

Cost-effectiveness Measures

TST

T-SPOT.TB

QFT-GIT

TST/T-SPOT.TB

TST/QFT-GIT

Total costs of screening

£199,589

£203,983

£202,921

£162,387

£157,048

Incremental cost of screening (compared to no screening)

£142,442

£146,836

£145,774

£105,240

£99,901

Active TB cases prevented

2.98

3.70

3.47

2.83

2.65

Cost per active TB case prevented

£67,034

£55,168

£58,536

£57,410

£59,265

Incremental cost per active case prevented (compared to no screening)

£47,840

£39,712

£42,051

£37,206

£37,699

Savings per active TB case prevented (compared to TST)

-

£8,128

£5,790

£10,634

£10,141

  1. All costs are expressed in British pounds (£). Cost-effectiveness relates to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)